KR102232623B1 - 결장직장암의 치료 방법 - Google Patents

결장직장암의 치료 방법 Download PDF

Info

Publication number
KR102232623B1
KR102232623B1 KR1020157029231A KR20157029231A KR102232623B1 KR 102232623 B1 KR102232623 B1 KR 102232623B1 KR 1020157029231 A KR1020157029231 A KR 1020157029231A KR 20157029231 A KR20157029231 A KR 20157029231A KR 102232623 B1 KR102232623 B1 KR 102232623B1
Authority
KR
South Korea
Prior art keywords
smad7
cells
colorectal cancer
antisense oligonucleotide
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020157029231A
Other languages
English (en)
Korean (ko)
Other versions
KR20150131260A (ko
Inventor
지오반니 몬텔레온
살바토레 벨린비아
비티 프란체스카
Original Assignee
노그라 파마 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 노그라 파마 리미티드 filed Critical 노그라 파마 리미티드
Publication of KR20150131260A publication Critical patent/KR20150131260A/ko
Application granted granted Critical
Publication of KR102232623B1 publication Critical patent/KR102232623B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/495—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/312—Phosphonates
    • C12N2310/3125—Methylphosphonates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/334—Modified C
    • C12N2310/3341—5-Methylcytosine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/341—Gapmers, i.e. of the type ===---===

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
KR1020157029231A 2013-03-15 2014-03-14 결장직장암의 치료 방법 Active KR102232623B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361790488P 2013-03-15 2013-03-15
US61/790,488 2013-03-15
US201361847287P 2013-07-17 2013-07-17
US61/847,287 2013-07-17
PCT/EP2014/055195 WO2014140333A1 (en) 2013-03-15 2014-03-14 Methods of treating colorectal cancer

Publications (2)

Publication Number Publication Date
KR20150131260A KR20150131260A (ko) 2015-11-24
KR102232623B1 true KR102232623B1 (ko) 2021-03-26

Family

ID=50390057

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020157029231A Active KR102232623B1 (ko) 2013-03-15 2014-03-14 결장직장암의 치료 방법

Country Status (11)

Country Link
EP (1) EP2970419B8 (https=)
JP (2) JP6502863B2 (https=)
KR (1) KR102232623B1 (https=)
CN (1) CN105008394B (https=)
AU (1) AU2014229985B2 (https=)
CA (1) CA2903597C (https=)
ES (1) ES2673209T3 (https=)
MX (1) MX363746B (https=)
NZ (1) NZ711564A (https=)
RU (1) RU2674147C2 (https=)
WO (1) WO2014140333A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITRM20030149A1 (it) 2003-04-02 2004-10-03 Giuliani Spa Oligonucleotidi (odn) antisenso per smad7 e loro usi in campo medico
ES2627745T3 (es) 2008-11-13 2017-07-31 Nogra Pharma Limited Composiciones antisentido, y procedimientos de fabricación y uso de las mismas
ES2617200T3 (es) 2011-09-15 2017-06-15 Nogra Pharma Limited Procedimientos para supervisar la capacidad de respuesta al tratamiento anti-SMAD7
US10081809B2 (en) 2012-04-18 2018-09-25 University Of Miami Methods of treating diabetes and/or promoting survival of pancreatic islets after transplantation
US10006029B2 (en) 2013-03-15 2018-06-26 Nogra Pharma Limited Methods of treating colorectal cancer
AU2015257589A1 (en) 2014-05-09 2016-11-24 Nogra Pharma Limited Methods for treating inflammatory bowel disease
WO2016059239A1 (en) 2014-10-17 2016-04-21 Nogra Pharma Limited Methods and compositions for treating a subject with a smad7 antisense oligonucleotide
MX2018003699A (es) * 2015-09-30 2018-08-01 Celgene Alpine Invest Company Ii Llc Moduladores de tlr y metodos de uso.
JP2019505598A (ja) 2016-02-23 2019-02-28 セルジーン アルパイン インベストメント カンパニー Ｉｉ， エルエルシー Ｓｍａｄ７の阻害を用いて、腸線維症を治療する方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005014011A1 (en) * 2003-08-11 2005-02-17 Giuliani S.P.A. Use of smad 7 antisense oligonucleotides (odn) for the treatment of diseases mediated by the nuclear transcription factor nf-kb

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6159697A (en) * 2000-01-19 2000-12-12 Isis Pharmaceuticals, Inc. Antisense modulation of Smad7 expression
ITRM20030149A1 (it) * 2003-04-02 2004-10-03 Giuliani Spa Oligonucleotidi (odn) antisenso per smad7 e loro usi in campo medico
US7402574B2 (en) * 2004-03-12 2008-07-22 Avi Biopharma, Inc. Antisense composition and method for treating cancer
US20080114287A1 (en) * 2006-11-14 2008-05-15 Kar Neng Lai Ultrasound Microbubble Mediated Genes Delivery System
ES2627745T3 (es) * 2008-11-13 2017-07-31 Nogra Pharma Limited Composiciones antisentido, y procedimientos de fabricación y uso de las mismas
UA107562C2 (uk) * 2008-12-05 2015-01-26 Спосіб лікування псоріазу
ES2617200T3 (es) * 2011-09-15 2017-06-15 Nogra Pharma Limited Procedimientos para supervisar la capacidad de respuesta al tratamiento anti-SMAD7

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005014011A1 (en) * 2003-08-11 2005-02-17 Giuliani S.P.A. Use of smad 7 antisense oligonucleotides (odn) for the treatment of diseases mediated by the nuclear transcription factor nf-kb

Also Published As

Publication number Publication date
CA2903597C (en) 2023-04-04
MX2015013255A (es) 2015-12-15
KR20150131260A (ko) 2015-11-24
JP2019026649A (ja) 2019-02-21
RU2674147C2 (ru) 2018-12-05
EP2970419B8 (en) 2019-12-11
EP2970419A1 (en) 2016-01-20
EP2970419B1 (en) 2018-05-09
RU2015140572A (ru) 2017-04-24
AU2014229985A1 (en) 2015-09-10
NZ711564A (en) 2020-04-24
CA2903597A1 (en) 2014-09-18
CN105008394A (zh) 2015-10-28
RU2015140572A3 (https=) 2018-03-21
WO2014140333A1 (en) 2014-09-18
ES2673209T3 (es) 2018-06-20
ES2673209T8 (es) 2020-02-12
CN105008394B (zh) 2021-10-22
AU2014229985B2 (en) 2018-12-13
MX363746B (es) 2019-04-01
JP6502863B2 (ja) 2019-04-17
JP2016517401A (ja) 2016-06-16
HK1219489A1 (en) 2017-04-07

Similar Documents

Publication Publication Date Title
KR102232623B1 (ko) 결장직장암의 치료 방법
US10006029B2 (en) Methods of treating colorectal cancer
Johnson et al. Protease-activated receptor-2 (PAR-2)-mediated NF-κB activation suppresses inflammation-associated tumor suppressor microRNAs in oral squamous cell carcinoma
KR20170031245A (ko) 염증성 장 질환을 진단 및 치료하기 위한 방법 및 조성물
JP2021106625A (ja) Ｉｌ−３４アンチセンスオリゴヌクレオチドおよびその使用方法
JP5611953B2 (ja) 癌の処置における治療標的としてのチロシンキナーゼ受容体ｔｙｒｏ３
WO2020256868A1 (en) Immune system modulators for the treatment of squamous lung premalignancy
US20220145303A1 (en) Fragile x mental retardation protein interfering oligonucleotides and methods of using same
WO2013166366A1 (en) Cul4b as predictive biomarker for cancer treatment
JP7236382B2 (ja) 抗癌剤及びその使用
HK1219489B (en) Methods of treating colorectal cancer
Mamishi Potential role of A2B Adenosine receptor in proliferation and metastasis of pancreatic cancer cells
WO2024086562A2 (en) Methods for treating or preventing neuroendocrine tumor formation using xpo1 inhibitors
EA045399B1 (ru) Олигонуклеотиды, препятствующие экспрессии белка, ассоциированного с синдромом ломкой х-хромосомы, и способы их применения

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20151014

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20190307

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20200724

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20210113

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20210322

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20210322

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20240307

Start annual number: 4

End annual number: 4